Anji Microelectronics: A High-Quality Compounder, but a Better Company Than Stock

This is a long trend rather than a fad. The annual report cites WSTS for a 2025 global semiconductor market of $795.6bn, up 26.2%, and cites SEMI’s expectation that the industry could reach the trillion-dollar mark by the end of 2026 under the combined push of AI and digitalization. Anji’s own industry exposition also notes that more advanced nodes, new materials, and advanced packaging increase both CMP step count and electronic-chemical demand. If compute gets more performance-dense and packaging-heavy, Anji’s addressable process wallet keeps widening.

If this structural trend runs for another three to five years, the industry structure changes in two ways. First, the winner set broadens beyond pure CMP into multi-product process-chemistry platforms. That is why Anji keeps emphasizing “3+1” rather than one hero product. Second, the Chinese market becomes less willing to tolerate single-point foreign dependence in critical materials. That does not mean every localized supplier wins. It means the suppliers that already cleared qualification barriers gain a much larger option set. Anji is one of the few Chinese names clearly in that bucket.

What the market may still underappreciate is not whether domestic substitution exists. That is already consensus. What may still be underappreciated is the duration of the share-gain runway if Anji can keep turning a CMP lead into a broader account-control position across cleaning, etching, plating, and partially localized upstream inputs. What the market may be overappreciating is the speed of that conversion at the current share price. Both statements can be true at once.

Usage and Unit Economics

The best starting point is the income statement, because Anji is a listed operating company, not a concept stock. In 2025 it generated CNY 2.504bn of revenue, CNY 783.65m of attributable net profit, CNY 696.55m of attributable profit ex non-recurring items, CNY 439.77m of operating cash flow, and a 25.18% weighted-average ROE. Revenue has compounded strongly across the last three disclosed years, from CNY 1.238bn in 2023 to CNY 1.835bn in 2024 and CNY 2.504bn in 2025. That is real usage showing up in real cash, not a market story hunting for a business model.

The revenue mix tells the same story, but with a useful nuance. CMP slurry still dominates, contributing CNY 2.040bn in 2025 and growing 32.06% year on year, with a gross margin of 58.28%. Functional wet electronic chemicals contributed CNY 452.86m and grew 63.73%, with a 50.00% gross margin. The company told investors in June 2026 that the biggest growth contribution in this second category came from cleaning products such as post-etch and post-polish cleaning, while electroplating liquids and additives are still smaller in revenue contribution but have already entered mass production in damascene and advanced-packaging use cases. The second curve is no longer theoretical; it is already visible in the P&L.

The unit-economics picture is good, though not perfect. Overall segment gross margin in integrated-circuit materials was 56.79% in 2025, down 1.66 percentage points from the prior year, while wet-chemicals margin improved sharply and CMP slurry margin eased. Management explained in the May 2026 investor exchange that this pattern mainly reflected product-mix changes and normal lifecycle-based positioning rather than a structural deterioration in competitiveness. I think that explanation is plausible because the company is simultaneously commercializing more products across more nodes and packaging use cases; during those transitions, mix should move around. What matters is that margins remain high enough to keep funding R&D at scale.

R&D remains unusually heavy by chemical-industry standards. In 2025, Anji spent CNY 444.70m on R&D, up 33.64% year on year, equal to 17.76% of revenue. It also disclosed 308 granted invention patents as of 2025-12-31 and 383 invention-patent applications accepted, with 106 invention-patent applications and 21 grants added during 2025. The company was also recognized in 2025 as a national enterprise technology center and as a Shanghai manufacturing single champion for CMP slurry. That does not guarantee future wins, but it does support the argument that the moat is technical and cumulative rather than purely relational.

Customer stickiness is high. The most important hard fact is the qualification mechanism. The company’s refinancing materials stated that only after strict qualification can a supplier become a qualified vendor, and once a vendor is qualified, changing suppliers is time-consuming and costly for the customer. The 2025 report then adds evidence that multiple copper-barrier products became first-choice suppliers at new clients and that advanced-packaging polishing products helped customers open up new technical routes. The sustainability summary says complaint-closure rate was 100% and customer-satisfaction pass rate was 100%, which I would not take too literally as an economic metric, but it is directionally consistent with a business model built around process support rather than one-off sales.

On fake prosperity, the report does not show the obvious warning signs. This is not a revenue model based on subsidies, wash volume, or circular counterparties. Core profit excluding non-recurring items still grew 32.36% in 2025, which is lower than headline net-profit growth but still strong. The company did disclose that non-recurring gains contributed CNY 87.09m, mainly from mark-to-market gains on external investments and project-acceptance-related other income, so the clean way to read the year is not the 46.85% headline but the 32.36% core-profit growth plus strong revenue growth. That is the right base for valuation.

Capex and capacity deserve special attention because this was one of the user’s named priorities. Cash paid for purchases of fixed assets, intangible assets, and other long-term assets rose to CNY 355.38m in 2025 from CNY 267.37m in 2024. Construction in progress rose to CNY 226.20m from CNY 166.53m. At the same time, the company completed an CNY 830.5m convertible bond issuance in April 2025, with 2025 year-end bonds payable of CNY 820.21m. By year-end, key projects included the Shanghai integrated-circuit-materials base project, an automation/informatization project for that base, a new 20,000-ton-per-year integrated-circuit-materials project in Ningbo, and R&D equipment and automation projects for the Shanghai Jinqiao base. The June 2026 investor-relations record said multiple added lines at Jinqiao and Ningbo Beilun were already in operation and the Shanghai Chemical Industry Park electronic-chemicals manufacturing base had topped out structurally.

That capex trajectory is rising, but it is not reckless. Operating cash flow of CNY 439.77m nearly covered 2025 capex cash outflow, and year-end cash and cash equivalents stood above CNY 1.106bn on the consolidated cash-flow statement. Short-term borrowings were only CNY 145.69m, and long-term borrowings net of current maturities were negligible; the main financial liability increase was the convert. Anji is funding expansion from a mix of healthy internal cash generation and a dedicated growth instrument, not from emergency balance-sheet stretching.

There is one usage-side caution worth stating plainly. The annual report shows raw-material inventory swelling materially, from about CNY 492.21m to CNY 865.94m. Management later explained that this reflected both preparation for business growth and deliberate strategic inventory to improve supply-chain resilience. That is reasonable in a tight-supply environment, and the June 2026 investor note said production and delivery remained stable, but it does tie up working capital and reminds investors that this is still a physical manufacturing business with real supply-chain friction.

Narrative Liquidity

Anji’s one-line story is strong because it is simple: China’s homegrown CMP-slurry champion is turning into a broader semiconductor-materials platform, and its global share is rising. That is a story institutional money, industrial policy believers, and retail momentum capital can all understand. The company helps because it has kept the narrative tightly framed around “3+1,” domestic substitution, advanced nodes, advanced packaging, and global expansion.

The narrative also has enough proof underneath it to avoid being thin air. Anyone can say “国产替代”; the disclosed numbers are what back it: global CMP share moving from 7% in 2022 to 11% in 2024 and 13% in 2025, plus a 63.73% surge in wet-chemicals revenue in 2025. That is why I would call Anji’s narrative healthy rather than dangerous: the story spreads because usage is improving, not because nothing is happening and the stock merely goes up.

Still, by late June 2026 the narrative has become crowded rather than ignored. The stock closed at CNY 304.80 on 2026-06-29, touched CNY 309.80 intraday, and was up about 161% over one year. Once a semiconductor-materials name has already rerated that hard, the marginal buyer is no longer discovering the company’s existence. The marginal buyer is underwriting acceleration. That changes the error bars. Good results are no longer enough by themselves; the company has to keep beating the speed embedded in the price.

This is where reflexivity matters. Rising price helps Anji in soft ways: it broadens attention, strengthens recruiting appeal, improves capital-market optionality, and makes the H-share plan easier to market. But the same chain runs backward. If the market decides that wet chemicals and plating will scale more slowly, or that overseas expansion remains gradual, the valuation can compress even while the business is still good. In this name, narrative is support, not foundation; but after the rally, narrative is also a larger source of downside than it was a year ago.

Bridge

The bridge question is whether Anji can connect hard-tech domestic substitution with broader pools of traditional capital and global commercial credibility. The clearest new fact here is the June 2026 announcement that the company is planning an H-share issue and listing in Hong Kong. The company said the purpose is to build an international capital-operations platform, widen diversified financing channels, enhance competitiveness, and deepen its global strategy. In the June 2026 investor-relations meeting, management repeated that framing and said details were not yet determined.

Hong Kong is more than a trading venue. For a STAR-board materials company, it is a bridge to offshore long-only capital, broader analyst coverage, and potentially easier communication with global customers and partners. In a business where qualification, trust, and local support matter, capital-market internationalization can have second-order commercial effects. I would not overstate that. An H-share listing does not improve slurry chemistry. But it can improve the company’s ability to finance capacity, local labs, overseas teams, and strategic cooperation without depending entirely on mainland capital conditions.

Commercially, the bridge already exists in early form. The company’s own materials say many overseas users increasingly recognize its R&D capability, and the June 2026 investor record says it is advancing local capability in Taiwan and expanding in Singapore, including local talent and laboratory set-up and active customer project tracking. That is the right kind of bridge: it is a lab-and-service footprint tied to validation and applications engineering, not just a PR event.

The limit is that Anji is still early in turning this international posture into visibly large overseas revenue. The 2023 refinancing prospectus showed that revenue still came overwhelmingly from mainland China, with 93.73% of 2022 revenue sourced there, though overseas and Taiwan revenue had been rising. I have not seen a refreshed 2025 geographic split in the materials reviewed that is detailed enough to prove a step-change in overseas mix. So the bridge is real, but still under construction.

Anti-cycle

This is not a counter-cyclical bargain in the sense of being cheap in a downcycle. The industry backdrop looks more like recovery to early upcycle. The 2025 annual report cites a strong semiconductor market rebound, and management’s June 2026 comments emphasize advanced-node demand, localization, and customer capacity expansion as external drivers over the next three to five years. From a cycle-timing perspective, Anji is being judged in favorable weather, not in a storm.

If the industry fell 50%, Anji would probably be more survivor than consolidator. It has more than CNY 1.1bn of cash and cash equivalents on the consolidated statement, access to convert-bond funding, and a rolling expansion plan. But management’s own language is telling: growth is centered on organic expansion, with an “open and prudent” stance toward external opportunities rather than a stated ambition to buy distressed assets aggressively. That is a sensible posture for a qualification-heavy materials business. Acquiring revenue is easy; acquiring trust inside customer process flows is not.

The counter-cyclical edge instead lies in continuing to invest while weaker rivals hesitate. The June 2026 investor note says Anji uses a “small steps, fast run, rolling planning” philosophy, building the physical environment for future production ahead of demand and then flexing line investment and ramping dynamically. That is a more credible anti-cycle playbook than heroic M&A claims. In a softer market, the company could use its balance sheet and project pipeline to keep qualifying new products and taking wallet share, even if it is not buying entire businesses.

So under SUN-R, Anti-cycle is a middling positive rather than a major pillar. Anji is not a distressed-asset hunter. It is a technically advantaged operator with enough financial strength to keep widening its moat when weaker players slow down.

Regulatory Reflexive and Ruin Risk

The right way to read Anji’s risk profile is that the most likely bad outcome is a severe derating, not a literal business-model collapse. But there are still several failure paths worth spelling out.

• Regulatory and sector-policy risk is medium probability and medium severity. Anji operates in a strategically encouraged sector, which helps, but its customers and supply chain sit inside a geopolitically sensitive semiconductor system. The company itself highlights semiconductor-cycle risk and FX risk, and its older refinancing materials showed a still-high dependence on non-mainland procurement for key inputs. The observable signals are tighter export controls on upstream materials and tools, slower domestic fab expansions, or delayed H-share approvals; the knock-on effect would be slower qualification progress, higher input costs, and lower enthusiasm for the global-expansion narrative.

• Supply-chain and counterparty risk is medium probability and high severity. The 2023 prospectus showed about 68% of procurement coming from outside mainland China in 2022, while the 2025 report stresses ongoing efforts to localize core raw materials and shows much larger raw-material inventory at year-end. Management said in June 2026 that production and delivery remained stable and that strategic inventory was being used to improve resilience. The signal to watch is whether inventory stays strategic and productive, or starts rising faster than sales because certain inputs are constrained or mismatched; if risk fires, gross margin and working-capital efficiency would both come under pressure.

• Customer-concentration and qualification risk is low-to-medium probability and high severity. I could not confirm a current top-customer concentration ratio from the reviewed materials, so I will not invent one. What is confirmed is that qualification cycles are long and switching is expensive once qualification is achieved. That cuts both ways: it protects incumbency, but it also means a contamination issue, quality failure, or missed-node transition at a major account could be painful and slow to repair. Observable signals would be sudden gross-margin weakness, unusual inventory builds in a specific product family, or language in disclosures shifting from “mass production” back to “validation”; the knock-on effect would be immediate multiple compression because the market prices Anji as a reliable share gainer.

• Governance risk is low probability and medium severity. The annual-report summary states there are no special governance arrangements, and this is a conventional A-share structure rather than a dual-class or token-like setup. That said, a high-multiple growth name can still hurt minority holders through poorly timed financing or overexpansion if discipline slips. The signal to watch is capital raising that outruns visible project returns, especially after the H-share plan; the knock-on effect would be a rapid shift from scarcity premium to dilution discount.

• Key-person and organization risk is medium probability and medium severity. This company depends more on process know-how and customer engineering than on a single celebrity founder, which is good. It also had 313 employees under stock-based incentives, equal to 39.87% of total staff on the company’s stated basis, which helps align technical talent. Even so, deep materials firms live or die on technical teams and customer-facing execution. The signals are abnormal technical-staff turnover, slower patent output, or deterioration in complaint handling; if this risk fires, the market would question whether the moat is institutional or personal.

• Reflexive valuation risk is high probability and high severity. This is the biggest near-term risk. The stock closed at CNY 304.80 on 2026-06-29 after a roughly 161% one-year rise, with unusually high trading volume and turnover that day. At this level, even a healthy business can produce a bad stock outcome if growth merely normalizes. The signal is simple: if 2026 results stay strong but fail to accelerate further, the market can still compress the multiple. When that happens, price weakness can cool narrative heat, make future financing less attractive, and reduce investors’ willingness to prepay distant optionality.

• Ruin risk is low probability but high severity if it occurs. I do not think the base-case downside is “goes to zero.” The more realistic worst case is losing key customer qualifications or suffering a material quality event at the same time as the cycle weakens and expansion projects absorb cash without rapid payback. That would not make the chemistry business disappear overnight, but it could break the premium-rating thesis and impose a 50% or worse drawdown. A true zero is much harder to justify here than in crypto or platform names, because there is a real production business and real customer use. The correct SUN-R framing is therefore ruin at the equity-price level through reflexive derating, not ruin at the existence level through obvious fraud or legal invalidity.

SUN-R Score

I score Anji as follows.

Structural shift earns 14 out of 15. The company sits on two durable trends at once: higher materials intensity per wafer and domestic substitution in critical semiconductor consumables. The evidence is not philosophical; it is in the disclosed share gains and product-platform breadth.

Real usage earns 19 out of 20. Revenue, profit, cash flow, and product-level growth all point to genuine adoption, and this is reinforced by the long qualification cycle and mass-production language in multiple product families.

Unit economics earn 12 out of 15. Gross margins remain high and ROE is excellent, but product mix is moving enough that I do not want to score it as if margins are perfectly stable. Wet chemicals improving while slurry margins slip modestly is manageable, not idealized.

Network effects earn 12 out of 15. This is not a consumer network, but there is a process-embedded flywheel: qualification leads to incumbency, incumbency leads to line-item expansion, and broader platform coverage deepens customer dependence. In a materials business, that is the relevant kind of network effect.

Narrative liquidity earns 10 out of 15. The story is simple and spreadable, and the market has clearly embraced it. The deduction is that the current valuation already reflects that embrace.

Bridge to the traditional world earns 7 out of 10. The H-share plan, Taiwan and Singapore expansion, and broader international-capital posture all matter, but the bridge is still developing rather than already monetized at scale.

Counter-cyclical opportunity earns 6 out of 10. The company has enough strength to keep investing through a downturn, but it is not obviously set up as a major distressed consolidator.

Regulatory and ruin risk deducts 10 points. The real issue is not existential legal risk; it is supply-chain sensitivity and, above all, reflexive valuation risk at a very elevated share price.

Total SUN-R score: 70

Tier: High-beta watch

【Project Standard Rating】Watch

Position Sizing and Tracking

For a balanced-risk investor, this is not a heavy-position stock at the current price. The business quality is high enough for long-term interest, but the entry point is not forgiving. I think it fits either a small starter position for investors who prioritize quality over valuation, or watch-only status for investors who want a better price before committing serious capital. The right time to size up comes when the market again offers a gap between execution quality and valuation, not when the story is newest.

The positive catalyst path is clear. More evidence that wet chemicals are a true second engine, visible revenue contribution from electroplating chemistry, continued overseas validation in Taiwan and Singapore, and orderly progress toward an H-share listing would all support the premium multiple. The negative catalyst path is just as clear. CMP growth slowing toward fab-capex growth, wet-chemical gross margin stalling, inventories staying elevated without corresponding shipment growth, or project build-out running ahead of utilization would all challenge the current pricing.

The next three months should be watched for half-year 2026 revenue mix, especially whether functional wet chemicals sustain their faster trajectory and whether CMP margin stabilizes. Over the next 12 months, the most important questions are whether Anji can keep pushing global CMP share higher from the 13% 2025 base, whether cleaning and plating chemistry meaningfully lift non-slurry revenue, and whether the Shanghai Chemical Industry Park site begins to translate from construction progress into visible capacity contribution. Over three years, the key judgment is whether Anji becomes a true multi-product process-chemistry platform rather than a premium CMP-slurry specialist with adjacent options.

My valuation work uses a blended framework: a 12-month earnings-multiple view for the public-market entry discipline, anchored by a 3–5-year view that Anji deserves a structural premium to generic chemical names because of qualification barriers, R&D intensity, and process criticality. The practical question is not “what is the perfect DCF value,” because this is a high-growth, project-heavy A-share hard-tech name. The practical question is what earnings multiple is fair for 2026–2027 if the company keeps compounding but no longer surprises the market every quarter.

I use three central assumptions. First, 2026 net profit likely grows but not at the same rate as the stock has rerated; a reasonable research range is roughly low-20s growth, supported by the positive Q1 2026 momentum in market summaries of the April filing and by management’s June 2026 comments. Second, premium valuation is justified, but some compression from current levels is normal once the stock trades near all-time highs. Third, the fair entry zone should require both good business quality and a margin of safety against narrative reversal.

The meaning behind these bands matters more than the arithmetic. The bear band is not a disaster case. It is the zone where I think the stock becomes properly attractive for long-term buying if execution remains intact and the market cools off. The base band is the fair-value hold zone for a name with a strong moat and a real second-growth curve. The bull band assumes the market continues to pay a scarcity premium for domestic hard-tech winners and accepts several years of growth in advance.

Ideal buy price range: 190–230 CNY

【Valuation Range】

• current: 304.80 (as of 2026-06-29)
• bear (conservative · ideal buy zone): [190, 230]
• base (fair · acceptable hold zone): [230, 280]
• bull (optimistic · fully-priced zone): [280, 340]
• mode: price

Scenario Analysis and Final Research Verdict

The main point of disagreement with the market is pace, not direction. I do not disagree that Anji is one of the best-positioned Chinese semiconductor-materials companies. I do disagree with the idea that any premium multiple is acceptable simply because the moat is real. Today’s price already assumes that the company converts CMP leadership into broader platform dominance without a meaningful pause in valuation. I lean less skeptical on the business than bears do, and more skeptical on the stock than bulls do.

The key tracking metrics are therefore obvious. On real usage, watch CMP revenue growth against wet-chemicals growth, and watch whether electroplating chemistry starts to matter at a P&L level. On narrative, watch whether the stock can digest elevated expectations without needing a new capital-markets headline every month. On risk, watch inventory intensity, raw-material localization progress, and whether project commissioning starts yielding utilization rather than just construction milestones. On bridge, watch the H-share process for concrete terms rather than broad aspiration.

My final verdict is that Anji is a high-quality hard-tech compounder with genuine structural tailwinds, but currently a better company than stock. It passes the SUN-R usage test comfortably. It also passes the moat test: qualification cycles are long, customer switching costs are high, R&D is heavy, and disclosed global share gains are hard to fake. The name fails only if one confuses those strengths with automatic undervaluation. At CNY 304.80, with the shares sitting near a record high after a 12-month surge, the risk-reward no longer turns on discovering a hidden leader; it turns on paying up for one and hoping execution outpaces already-high expectations.

That is why the right research conclusion is High-beta watch, mapped to Watch. If the stock returned to the 190–230 CNY range without a corresponding break in fundamentals, I would regard that as a serious re-underwriting zone. At current levels, I would rather miss some upside than pay for perfection. The reasons it could rerate higher are clear: continued share gains, successful second-curve scaling, and improved overseas and capital-market reach. The reasons it could halve are equally clear: multiple compression, slower-than-implied wet-chemical monetization, or project and margin execution that stays good but not exceptional. The reason it could go close to a permanent-loss case is a quality or qualification failure hitting at the same time expansion capital is already committed, breaking the premium multiple and the “inevitable winner” narrative together; slurry does not suddenly become useless.

【Fair Buy Price】190–230 CNY Basis: blended 2026E earnings-multiple framework for a premium semiconductor-materials compounder, requiring a valuation reset large enough to compensate for reflexive and execution risk.

Information uncertainty remains in four places. I could not confirm a fresh, company-wide 2025 mainland CMP-slurry market-share figure from primary disclosure, only older third-party mainland estimates and newer global-share disclosures. I could not confirm the current top-customer concentration ratio from the reviewed materials. I could not confirm final H-share issuance terms because the plan remains preliminary. And I would want the 2026 interim report before taking a stronger near-term valuation stance, especially for product mix, inventories, and new-line utilization.

This is analysis under a research framework, not investment advice.

Other tickers mentioned

• ENTG.US: global benchmark in CMP and adjacent semiconductor materials after the CMC Materials acquisition
• 300236.SHE: domestic peer spanning wet chemicals, plating additives, and CMP slurries
• 603078.SHG: domestic wet-electronic-chemicals peer focused on high-purity reagents and photoresist ancillaries
• 5384.TSE: Fujimi, a longstanding Japanese CMP-materials peer referenced in Anji’s competitive disclosures

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.